Inclusion:

          -  Patients must have a pathologically or cytologically confirmed carcinoma (except
             neuroendocrine) of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or
             gallbladder) that is not eligible for curative resection, transplantation, or ablative
             therapies. Tumors of mixed cholangiocarcinoma/hepatocellular carcinoma histology are
             excluded.

          -  Patients may not have received prior systemic treatment (chemotherapy or targeted
             therapy) for advanced BTC. Prior peri-operative chemotherapy is permitted provided it
             was completed > 6 months from enrollment.

          -  Patients may have received prior radiation, chemoembolization, radioembolization or
             other local ablative therapies or hepatic resection if completed ≥ 4 weeks prior to
             enrollment AND if patient has recovered to ≤ grade 1 toxicity. Extrahepatic palliative
             radiation is permitted if completed ≥ 2 weeks prior to enrollment AND if patient has
             recovered to ≤ grade 1 toxicity

          -  Patients must have radiographically measurable disease (as per RECISTv1.1) in at least
             one site not previously treated with radiation or liver directed therapy (including
             bland, chemo- or radio-embolization, or ablation) either within the liver or in a
             metastatic site.

          -  Must be ≥ 18 years of age.

          -  Must have an ECOG performance status of 0-1.

          -  Ability to understand and willingness to sign IRB-approved informed consent.

          -  Willing to provide archived tissue, if available, from a previous diagnostic biopsy.

          -  Must be able to tolerate CT and/or MRI with contrast.

          -  Adequate organ function (per protocol) obtained ≤ 2 weeks prior to enrollment.

          -  Women of child-bearing potential and men must agree to use 2 methods of adequate
             contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study
             entry, for the duration of study participation and for 6 months (for men and women)
             following completion of study therapy.

        Exclusions:

          -  Prior history of brain metastasis (unless previously treated, asymptomatic and stable
             for at least 3 months) or organ transplant.

          -  Underwent a major surgical procedure < 4 weeks prior to enrollment.

          -  Active second malignancy other than in situ cancer or localized prostate cancer
             (Gleason score <8). Patients with history of other malignancy are eligible provided
             primary treatment of that cancer was completed > 1 year prior to enrollment and the
             patient is free of clinical or radiologic evidence of recurrent or progressive
             malignancy.

          -  Ongoing active, uncontrolled infection (must be afebrile for > 48 hours off
             antibiotics) .

          -  Psychiatric illness, other significant medical illness, or social situation which, in
             the investigator's opinion, would limit compliance or ability to comply with study
             requirements.

          -  Pregnancy or breastfeeding. (Women must not be pregnant or breastfeeding since study
             drugs may harm the fetus or child. All females of childbearing potential [not
             surgically sterilized and between menarche and 1 year post menopause] must have a
             negative screening pregnancy test.)

          -  Active heart disease including symptomatic heart failure (NYHA class 3 or 4), unstable
             angina pectoris, uncontrolled cardiac arrhythmia or interstitial lung disease.

          -  Prisoners or subjects who are involuntarily incarcerated, or compulsorily detained for
             treatment of either a psychiatric or physical (e.g. infectious disease) illness would
             be excluded.

          -  Prolonged QTcF interval >480 msec.

          -  Known hypersensitivity to cisplatin, gemcitabine or CPI-613, or its inactive
             components.